Wexford Laboratories Adds Dexketoprofen 50mg/2ml Injectable Solution to Its Product List, Offering Rapid and Effective Relief for Acute Pain
March 2024: In a continuous effort to improve the quality of life for patients suffering from acute pain, Wexford Laboratories is proud to announce the launch of its new product: Dexketoprofen 50mg/2ml Injectable Solution. This innovative medication is designed to provide rapid and effective pain relief, serving as a valuable tool for healthcare professionals in various clinical settings.
Efficacy and Speed in Pain Relief
Dexketoprofen is a nonsteroidal anti-inflammatory drug (NSAID) that works by inhibiting the synthesis of prostaglandins, substances responsible for pain and inflammation. The 50mg/2ml injectable formulation allows for rapid absorption and action within the body, providing pain relief in significantly less time compared to oral formulations. This makes it an ideal option for managing postoperative pain, renal colic, severe musculoskeletal pain, and other types of acute pain.
Commitment to Health
With the launch of Dexketoprofen 50mg/2ml Injectable Solution, Wexford Laboratories reaffirms its commitment to patient well-being. This new product is a valuable addition to the company’s pain management solutions portfolio, providing healthcare professionals with an effective tool to improve their patients’ quality of life.
